A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)

Trial Identifier: 1235-CL-0101
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: November 2016
Primary Completion Date: September 2020
Condition: Leukemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, ON Toronto, ON, Canada, M5G 2M9
United States of America, CA Duarte, CA, United States of America, 91010
United States of America, MA Boston, MA, United States of America, 02114
United States of America, MD Baltimore, MD, United States of America, 21287
United States of America, NY New York, NY, United States of America, 10016
United States of America, TX Houston, TX, United States of America, 77030